This site is intended for Healthcare professionals.
×

Rare case of Calcinosis in Juvenile Dermatomyositis reported in NEJM


Rare case of Calcinosis in Juvenile Dermatomyositis reported in NEJM

Dr Jianguo Li and associates at Affiliated Children’s Hospital of Capital Institute of Pediatrics, Beijing, China have reported a rare case of Calcinosis in Juvenile Dermatomyositis. The case has appeared in the New England Journal of Medicine.

Juvenile Dermatomyositis (JDM) is a rare childhood systemic autoimmune disease characterized by proximal muscle weakness and rashes due to chronic muscle and skin inflammation of unknown aetiology. Calcinosis is one of the hallmark sequelae of juvenile dermatomyositis (JDM), and despite recent progress in the therapy of JDM, dystrophic calcification still occurs in approximately one-third of patients

 

................................ Advertisement ................................

A 4-year-old girl with juvenile dermatomyositis was brought to the rheumatology clinic with a rash and limb weakness. She had had continuous disease activity without remission despite receiving treatment with multiple medications, including glucocorticoids, intravenous immune globulin, methotrexate, and cyclosporine, over a period of 3 years at another hospital. On physical examination, the patient had erythematous changes to the skin overlying the finger, knee, and elbow joints (findings consistent with Gottron’s sign), heliotrope rash around the eyes, proximal muscle weakness in the arms and legs, and diffuse, palpable subcutaneous nodules. A radiograph of the pelvis showed extensive calcification (Panel A).

................................ Advertisement ................................

Courtesy NEJM

Magnetic resonance imaging of the thighs revealed muscle inflammation and calcinosis. The results of laboratory testing showed strong anti–nuclear matrix protein 2 (anti–NXP-2) autoantibody positivity, a finding associated with calcinosis in juvenile dermatomyositis. Given the patient’s refractory juvenile dermatomyositis and severe calcinosis, treatment with infliximab, thalidomide, and aluminum hydroxide was initiated. Two months after treatment, the patient had improved muscle strength and fading of the rash. At 9 months of treatment, a repeat radiograph showed that the calcinosis had decreased (Panel B).

for further reference log on to:

DOI: 10.1056/NEJMicm1809669

 




Source: New England Journal of Medicine

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted